Viridian Therapeutics Shares Rise on Positive Results of Veligrotug in Thyroid Eye Disease Trial

By MarketWatch | Sep 10, 2024 at 07:56 AM EST

Viridian Therapeutics stock surged before market open following positive phase 3 trial results for their thyroid eye disease treatment. The VRDN-001 treatment showed significant efficacy and safety in the Thrive trial, boosting shares by nearly 14%.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.